In the Annual Return GSTR 9:
Part I covers basic details of the taxpayer in Tables 1, Table 2 and Table 3,
Part II covers the details on Outward Supplies . Most of the Part II is auto-populated. using GSTR 1, 3B and other returns filed with the Government.
Part III constitutes details on inward supplies and ITC details in Table 6, 7 and 8 , only some of the details can be derived from the data available at GST system. Rest needs to be computed by the taxpayers. We have previously covered details on ITC availed as declared in returns filed during the financial year in Table 6.
In this blog, let us look at the next table i.e. Table 7 in GSTR 9 related to ITC reversal .
GSTR 9C is an annual audit form for all the taxpayers having the turnover above 2 crores in a particular financial year. It includes reconciliation Statement for a particular FY to be filed by taxpayers on or before 31st December after being certified by CAs/CMA. However, the due date for the same has been extended to 30th June 2019 in the 31st GST Council Meeting. It must be filed along with or after filing of the GSTR-9 i.e. GST annual return.
GST ITC-01 is a ( Declaration for claim of input tax credit under sub-section 1 of section 18 ).
GST ITC-02 is a ( Declaration for transfer of ITC in case of sale, merger, demerger, amalgamation, lease or transfer of a business under sub-section 3 of section 18 ).
GST ITC-02A is a ( Declaration for transfer of ITC pursuant to registration under sub-section 2 of section 25 ).
GST ITC-03 is a ( Declaration for intimation of ITC reversal/payment of tax on inputs held in stock, inputs contained in semi-finished and finished goods held in stock and capital goods under sub-section 4 of section 18 ).
GST ITC-04 is a ( Details of goods sent to job worker and received back )
Tax officer can cancel the GST registration where (a) taxpayer has not filed a return for six consecutive months (b) ITC availed in violation of statutory provisions https://www.taxgyata.com/ap/cancellation-of-registration-under-gst/
COVID-19 Impact Analysis on Anticoagulant Reversal Drugs Market report published by Value Market Research provides a detailed market analysis comprising market size, share, value, growth and trends for the period 2019-2027.
The report encompasses data regarding market share and recent developments by key players.
Moreover, this market report also covers regional and country markets in detail.The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide.
The major players in the Anticoagulant Reversal Drugs include Portola Pharmaceuticals, CSL Behring, Boehringer Ingelheim, Octapharma AG, AMAG Pharmaceuticals, Inc., Dr. Reddy's Laboratories, Pfizer, Inc., Fresenius Kabi AG, Bausch Health Companies Inc., Octapharma AG, SGPharma Pvt.
Ltd., and Alps Pharmaceutical Ind.
This section includes a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.Get more information on "Global Anticoagulant Reversal Drugs Research Report" by requesting FREE Sample Copy at https://www.valuemarketresearch.com/contact/anticoagulant-reversal-drugs-market/download-sampleMarket SegmentationThe broad Anticoagulant Reversal Drugs has been sub-grouped into the Product Type, Distribution Channel and Region.